Wang Linjuan, Qiu Yue, Huang Xiang, Zhang Shimei, Zhao Min, Chen Qiufang
Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, 361000, China.
Department of Pharmacy, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.
Lipids Health Dis. 2025 Jul 30;24(1):255. doi: 10.1186/s12944-025-02559-w.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly enhanced survival rates among patients with advanced non-small cell lung cancer (NSCLC) exhibiting EGFR mutations. However, acquired resistance diminishes their therapeutic efficacy over time. Recent investigations have linked intracellular cholesterol with the emergence and advancement of various cancers. Elevated cholesterol levels could correlate with resistance to EGFR-TKIs in NSCLC. This review examines the association between cholesterol and EGFR-TKI resistance in NSCLC, with the objective of identifying more effective treatments and surmounting resistance.
表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）显著提高了表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）患者的生存率。然而，随着时间的推移，获得性耐药会降低其治疗效果。最近的研究将细胞内胆固醇与各种癌症的发生和发展联系起来。胆固醇水平升高可能与NSCLC患者对EGFR-TKIs的耐药性相关。本综述探讨了NSCLC中胆固醇与EGFR-TKI耐药性之间的关联，旨在确定更有效的治疗方法并克服耐药性。
